<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">INSULIN INJECTION CONCENTRATED</span><br/>(in'su-lin)<br/><span class="topboxtradename">Iletin II Regular (Concentrated), </span><span class="topboxtradename">U-500<br/></span><b>Classifications:</b> <span class="classification">hormone and synthetic substitute</span>; <span class="classification">antidiabetic agent</span><br/><b>Prototype: </b>Insulin<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>500 units/mL</p>
<h1><a name="action">Actions</a></h1>
<p>Concentrated insulin from purified pork pancreas unmodified by any agent that might prolong its action. Because of its high
         concentration, duration of action is similar to that of an intermediate-acting insulin.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>It lowers blood glucose levels by increasing peripheral glucose uptake, especially by skeletal muscle and fat tissue, and
         by inhibiting the liver from changing glycogen to glucose.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Only for the occasional patient who develops insulin resistance and requires daily doses greater than 200 U (even as high
         as several thousand units).
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>During episodes of hypoglycemia or in patients sensitive to any ingredient in the formulation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>In insulin resistant patients, hyperthyroidism or hypothyroidism; lactation, older adults, pregnancy (category B), renal or
         hepatic impairment. Safety and efficacy in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Diabetes Mellitus</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SC</span> Individualized doses<br/><br/><p><span class="rdpostnotetext">(see <small>INSULIN, REGULAR</small>)</span></p>
</td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Subcutaneous</span><br/><ul>
<li>Do <small>NOT</small> give this preparation by IV because of a high risk of allergic or anaphylactoid reaction.
         </li>
<li>Use a tuberculin syringe for accuracy in measurement. Even a slight variation can cause a large overdose or underdose.</li>
<li>Store in a cold place, preferably a refrigerator, unless otherwise directed. Avoid freezing.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle"></span><p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span> <b>Regular insulin with aminophylline, amobarbital, chlorothiazide, dobutamine, pentobarbital, phenobarbital, phenytoin, secobarbital,
                     sodium bicarbonate, thiopental.</b>
</p>
</td>
</tr>
</table>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1>(see <small>INSULIN INJECTION, REGULAR</small>). 
      <h1><a name="interactions">Interactions</a></h1>(see <span class="classification">insulin injection</span>, <span class="classification">regular</span>). 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Onset:</span> 0.51 h regular. <span class="typehead">Peak:</span> 23 h regular. <span class="typehead">Duration:</span> 57 h regular. <span class="typehead">Metabolism:</span> Metabolized in liver and kidney. <span class="typehead">Elimination:</span> Half-Life: Up to 13 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p>(see <small>INSULIN INJECTION</small>, <small>REGULAR</small>)
      </p>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Keep patients receiving concentrated insulin under close surveillance until dosage is established. Close monitoring for symptoms
            of hypoglycemia, hyperglycemia, allergic or anaphylactoid reactions, and of water and electrolyte imbalance is essential.
         </li>
<li>Have on hand glucagon, IV dextrose, epinephrine. Severe secondary hypoglycemia reactions may develop 1824 h after administration
            of drug.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Be alert for and immediately report S&amp;S of severe hypoglycemia, which may develop up to 24 h after administration of drug.</li>
<li> 							Note: Responsiveness to insulin effect is frequently regained after a short period of therapy with concentrated insulin. 						</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>